Screener
CRISPR Therapeutics CRSP Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating activities: | ||
| Net loss | $(122,931) | $(135,996) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4,319 | 4,736 |
| Equity-based compensation | 16,324 | 20,212 |
| Other non-cash items, net | 8,800 | 2,253 |
| Changes in: | ||
| Accounts receivable | — | 25,000 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's net income?
- CRISPR Therapeutics (CRSP) reported net income of -$122.93M in Q1 2026.
- How has CRISPR Therapeutics's net income changed year-over-year?
- CRISPR Therapeutics's net income increased by 9.6% year-over-year, from -$136M to -$122.93M.
- What is the long-term trend for CRISPR Therapeutics's net income?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's net income has grown at a -5.4% compound annual growth rate (CAGR), from -$650.18M to -$581.6M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about CRISPR Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude